Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes.
Fiche publication
Date publication
mai 2023
Journal
Cardiovascular diabetology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DUVILLARD Laurence, Pr PETIT Jean-Michel, Pr VERGES Bruno, Dr PAIS DE BARROS Jean-Paul, Mme BATAILLE Amandine
Tous les auteurs :
Denimal D, Bergas V, Pais-de-Barros JP, Simoneau I, Demizieux L, Passilly-Degrace P, Bouillet B, Petit JM, Rouland A, Bataille A, Duvillard L, Vergès B
Lien Pubmed
Résumé
Emerging evidence supports that dihydroceramides (DhCer) and ceramides (Cer) contribute to the pathophysiology of insulin resistance and liver steatosis, and that their circulating concentrations are independently associated with cardiovascular outcomes. Circulating DhCer levels are increased in patients with type 2 diabetes (T2D). On the other hand, the GLP-1 receptor agonist liraglutide reduces major adverse cardiac events, insulin resistance and liver steatosis in T2D patients. The main purpose of the present study was therefore to investigate whether liraglutide decreases circulating levels of DhCer and Cer in T2D patients, which could be a mechanism involved in its cardiometabolic benefits. The secondary purpose was to assess the relationship between liraglutide-induced changes in DhCer/Cer levels and insulin resistance and liver steatosis.
Mots clés
Ceramides, Dihydroceramides, Liraglutide, Type 2 diabetes
Référence
Cardiovasc Diabetol. 2023 05 4;22(1):104